Gaggianesi et al. studied the impact of blocking IL-4 with the IL4Rα antagonist IL4DM in mammary gland tumors, reporting the inhibition of cancer cell proliferation, invasion, and growth that was achieved by downregulating mitogen-activated protein kinase (MAPK) pathway activity [19]. The gene discussed is IL4; the disease is cancer.